An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
The purpose of this clinical research study is to compare the confirmed complete cytogenetic response of dasatinib with that of imatinib within 12 months after randomization in patients with newly diagnosed chronic-phase Philadelphia positive chronic myeloid leukemia. The safety of this treatment will also be studied.
Key Inclusion Criteria:
Key Exclusion Criteria:
Buenos Aires, Buenos Aires 1021, Argentina
Capital Federal, Buenos Aires 1280, Argentina
Capital Federal, Buenos Aires C1114AAN, Argentina
Kamogawa-shi, Chiba 2968602, Japan
Bunkyo-ku, Tokyo 113-8677, Japan
Shinagawa-ku, Tokyo 1418625, Japan